Osteonecrosis of the jaws during treatment with bisphosphonates: Diagnosis and therapic options;Kieferosteonekrosen unter bisphosphonattherapie: Diagnostik und therapie

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 38, 2005, Pages 2142-2145

  Steiner, Beate ^a   Lenz, J H ^b   Gundlach, K K H ^b   Freund, M ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Universitatsklin Freiburg i Brsg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; STEROID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ANTIBIOTIC THERAPY; ARTICLE; BONE NECROSIS; DIAGNOSTIC PROCEDURE; DRUG INDICATION; HISTOLOGY; HUMAN; JAW DISEASE; JAW RADIOGRAPHY; PLASTIC SURGERY; RISK FACTOR;

DIPHOSPHONATES; HUMANS; JAW DISEASES; OSTEONECROSIS;

EID: 25844504727     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-916355     Document Type: Article

References (17)

1. Bauss F, Body JJ. Ibandronate in metastatic bone disease: a review of preclinical data. Anticancer Drugs 2005; 16: 107-118
2. Bjarnason NH. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N Engl J Med 2004; 35: 190-192
3. Bundesärztekammer. UAW-News - International: Osteonekrosen des Kiefers unter Bisphosphonaten. Dtsch Ärzteblatt 2004; 31-32: 2203
4. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 2003; 48: 268
5. Carter GD, Goss AN, Doecke CH. Bisphosphonates and avascular necrosis of the jaws: a possible association. MJA 2005; 413-415: 182
6. Conte PF, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9: 28-37
7. de Vos FY, Willemse PH, de Vries EG et al. Endothelial cell effects of cytotoxics: balance between desired and unwanted effects. Cancer Treat Rev 2004; 30: 495-513
8. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Rev Res 2004; 55: 210-244
9. Ludwig H. Supportive therapies in the management of myeloma. Oncology 2004; 18: 295-296
10. Marx R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1118
11. Michigami T, Hiraga T, Williams PJ et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 2002; 75: 249-258
12. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253-4254
13. Ruggiero SL, Mehrotra B, Rosenberg TJ et al. Osteonecrosis of the jaws with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534
14. Schwartz HC. Osteonecrosis and bisphosphonates: Correlation versus causation. J Oral Maxillofac Surg 2004; 62: 763-764
15. Sung EC, Chan SM, Sakurai K et al. Osteonecrosis of the maxilla as a complication to chemotherapy: a case report. Spec Care Dentist 2002; 22: 142-146
16. Tarassoff P, Csermak K. Avascular necrosis of the jaws: Risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003; 61: 1238-1239
17. Vannucchi AM, Ficarra G, Antonioli E et al. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. BJH 2005; 128: 738